meta:
  schema_version: '1.0'
  generated_by: Dawn (literature curation)
  last_updated: '2026-02-13'
  compatible_engine: cellswarm>=2.0
pathway_id: apoptosis_intrinsic
pathway_name: Intrinsic (Mitochondrial) Apoptosis
category: cell_death
kegg_id: hsa04210
components:
  receptors: []
  ligands: []
  downstream:
  - BAX
  - BAK1
  - BCL2
  - BCL2L1
  - MCL1
  - CYCS
  - APAF1
  transcription_factors:
  - TP53
  key_genes:
  - BAX
  - BAK1
  - BCL2
  - BCL2L1
  - MCL1
  - BID
  - CYCS
  - APAF1
  - CASP9
  - CASP3
signal_fields_affected:
- oxygen
- glucose
cell_type_effects:
  CD8_T:
    when_active: Intrinsic apoptosis eliminates exhausted or over-activated T cells.
      BCL2 family balance determines T cell lifespan in TME.
    behavioral_mapping:
      apoptosis: 0.3
      attack: -0.15
      proliferate: -0.1
    state_effects:
      survival: -0.3
      exhaustion: 0.1
  Tumor:
    when_active: Tumor cells frequently evade intrinsic apoptosis via BCL2/MCL1 overexpression
      or TP53 loss. Restoring apoptosis is a therapeutic strategy.
    behavioral_mapping:
      apoptosis: 0.25
      proliferate: -0.2
      evade: -0.15
    state_effects:
      survival: -0.3
  Treg:
    when_active: Tregs are relatively resistant to apoptosis in TME due to high BCL2
      expression.
    behavioral_mapping:
      apoptosis: 0.15
      suppress: -0.1
    state_effects:
      survival: -0.15
  Macrophage:
    when_active: Macrophage apoptosis reduces TME inflammation. Efferocytosis of apoptotic
      cells promotes M2 polarization.
    behavioral_mapping:
      apoptosis: 0.2
      phagocytose: -0.1
      polarize: 0.1
    state_effects:
      survival: -0.2
      m2_polarization: 0.1
  NK:
    when_active: NK cells undergo apoptosis upon chronic activation or cytokine withdrawal.
    behavioral_mapping:
      apoptosis: 0.25
      attack: -0.15
    state_effects:
      survival: -0.25
  B_cell:
    when_active: Germinal center B cells undergo apoptosis if they fail selection.
      BCL6 protects from premature apoptosis.
    behavioral_mapping:
      apoptosis: 0.2
      signal: -0.1
    state_effects:
      survival: -0.2
crosstalk:
- pathway: TP53_pathway
  type: activating
  description: p53 transcriptionally activates BAX, PUMA, NOXA to trigger intrinsic
    apoptosis
- pathway: PI3K_AKT_mTOR
  type: antagonistic
  description: AKT phosphorylates and inactivates BAD, blocking intrinsic apoptosis
- pathway: TNF_NFKB
  type: antagonistic
  description: NF-kB upregulates BCL2 and BCL-XL, inhibiting intrinsic apoptosis
targeted_by: []
references:
- description: BCL-2 family in cancer. Czabotar et al. Nat Rev Mol Cell Biol 2014
  pmid: '24355989'
  pmid_verified: true
- description: 'Hallmarks of cancer: next generation. Hanahan & Weinberg. Cell 2011'
  pmid: '21376230'
  pmid_verified: true
additional_agents:
- drug_id: venetoclax
  mechanism: BCL2 inhibitor, restores intrinsic apoptosis
  in_drug_library: false
- drug_id: navitoclax
  mechanism: BCL2/BCL-XL/BCL-W inhibitor
  in_drug_library: false
data_calibration:
  source: GSE176078 TNBC scRNA-seq (CellChat-lite)
  n_cells: 997
  communication_strength: 0.0133
  max_communication_strength: 0.0253
  n_active_pairs: 3
  top_interactions:
  - sender: NK
    receiver: Tumor
    ligand: TNFSF10
    receptor: TNFRSF10B
    probability: 0.0253
  - sender: CD8_T
    receiver: Tumor
    ligand: TNFSF10
    receptor: TNFRSF10A
    probability: 0.0075
  - sender: NK
    receiver: Tumor
    ligand: TNFSF10
    receptor: TNFRSF10A
    probability: 0.0071
